Top 50 Biotechnology Startup Investors in China (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
96 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$120M |
|
HSG
VC Fund
|
57 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Software, Health Care | $2M–$200M |
|
BioVenture
VC Fund
|
43 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$85M |
|
Matrix Partners China
VC Fund
|
39 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Information Technology | $1.4M–$137M |
|
Lilly Asia Ventures
VC Fund
|
39 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Kaitai Capital
VC Fund
|
33 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
Legend Capital
VC Fund
|
31 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
Med-Fine Capital
VC Fund
|
31 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
IDG Capital
VC Fund
|
30 | China, United States, Singapore | Series A, Series B, Seed | Internet, Software, E-Commerce | $600k–$110M |
|
Frees Fund
VC Fund
|
30 | China, United States, Singapore | Series A, Angel, Seed | Artificial Intelligence, Health Care, Medical | $447k–$28M |
|
Northern Light Venture Capital
VC Fund
|
26 | China, United States, South Korea | Series A, Series B, Venture - Series Unknown | Health Care, Medical, Biotechnology | $1.5M–$60M |
|
Sherpa Healthcare Partners
VC Fund
|
23 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7.2M–$128M |
|
Longpan Investment
VC Fund
|
22 | China, United States, Cayman Islands | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $14M–$60M |
|
Shenzhen Capital Group
VC Fund
|
22 | China, United States, Japan | Series A, Series B, Seed | Manufacturing, Health Care, Software | $1.4M–$141M |
|
CDH Investments
VC Fund
|
21 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $2.9M–$220M |
|
Highlight Capital
VC Fund
|
20 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.1M–$84M |
|
Green Pine Capital Partners
VC Fund
|
20 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Manufacturing | $425k–$150M |
|
Puhua Capital
VC Fund
|
18 | China, United Kingdom, United States | Series A, Series B, Seed | Manufacturing, Health Care, Medical | $1.5M–$103M |
|
Gaorong Capital
VC Fund
|
18 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Information Technology, Software | $1.6M–$110M |
|
Cowin Capital
VC Fund
|
18 | China, United States, Hong Kong | Series A, Series B, Seed | Manufacturing, Health Care, Semiconductor | $1.4M–$51M |
|
TF Capital
VC Fund
|
18 | China, United States | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$1.4B |
|
Linear Capital
VC Fund
|
18 | China, Singapore, United States | Seed, Angel, Series A | Artificial Intelligence, Software, Manufacturing | $1.4M–$122M |
|
Hillhouse Investment
VC Fund
|
18 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $2.9M–$300M |
|
Addor Capital
VC Fund
|
18 | China, Hong Kong, United States | Series A, Series B, Venture - Series Unknown | Manufacturing, Semiconductor, Electronics | $1.4M–$145M |
|
Pan-Lin Capital
VC Fund
|
17 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$58M |
|
Delian Capital
VC Fund
|
17 | China, United States, France | Series A, Seed, Series B | Biotechnology, Manufacturing, Health Care | $1.5M–$50M |
|
ZhenFund
VC Fund
|
16 | China, United States, Singapore | Seed, Series A, Angel | Artificial Intelligence, Software, E-Commerce | $121k–$22M |
|
Prox Ventures
VC Fund
|
15 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$30M |
|
Legend Star
VC Fund
|
15 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Robotics | $425k–$52M |
|
CD Capital
VC Fund
|
15 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Beijing Huafang Investment
VC Fund
|
15 | China | Series A, Seed, Angel | Biotechnology, Medical, Biopharma | $13M–$30M |
|
Oriental Fortune Capital
VC Fund
|
15 | China, United States, Hong Kong | Series A, Series B, Seed | Manufacturing, Software, Artificial Intelligence | $1.5M–$100M |
|
Taiyu Investment
VC Fund
|
15 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $434k–$100M |
|
Lenovo Capital
VC Fund
|
14 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.4M–$150M |
|
K2VC
VC Fund
|
14 | China, United States, Hong Kong | Angel, Series A, Seed | E-Commerce, Manufacturing, Software | $417k–$25M |
|
Shunwei Capital
VC Fund
|
14 | China, United States, India | Series A, Series B, Seed | Manufacturing, Software, Artificial Intelligence | $1M–$74M |
|
SDIC Venture Capital
VC Fund
|
14 | China, United States, Hong Kong | Series B, Series A, Series C | Manufacturing, Biotechnology, Electronics | $3M–$129M |
|
Cowin Venture
VC Fund
|
14 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Biotechnology, Medical | $52k–$257M |
|
Baidu Ventures
VC Fund
|
14 | China, United States, Singapore | Series A, Seed, Series B | Artificial Intelligence, Health Care, Robotics | $1.5M–$123M |
|
Huagai Capital
VC Fund
|
13 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $444k–$90M |
|
BioTrack Capital
VC Fund
|
13 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
Hillhouse Ventures
VC Fund
|
13 | China, Singapore, Norway | Series A, Series B, Seed | Manufacturing, Biotechnology, Health Care | $10M–$120M |
|
Oriza Holdings
VC Fund
|
13 | China, United States, Canada | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.5M–$100M |
|
5Y Capital
VC Fund
|
13 | China, United States, India | Series A, Series B, Series C | Artificial Intelligence, Software, Biotechnology | $3M–$400M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
13 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$159M |
|
Shunxi Fund
VC Fund
|
13 | China | Series A, Seed, Series B | Biotechnology, Manufacturing, Artificial Intelligence | $2.4M–$90M |
|
OrbiMed
VC Fund
|
12 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9M–$160M |
|
Lapam Capital
VC Fund
|
12 | China, United States | Series A, Series B, Series C | Biotechnology, Pharmaceutical, Health Care | $4.5M–$100M |
|
Innoangel Fund
VC Fund
|
12 | China, United States, Hong Kong | Angel, Seed, Series A | Artificial Intelligence, Manufacturing, Robotics | $425k–$29M |
|
LYFE Capital
VC Fund
|
11 | China, United States, France | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $11M–$148M |
| Access all 3405 investors in China Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1200
- Round size: Series A $4.3M–$48M; Series B $8M–$90M; Series C $12M–$120M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1091
- Round size: Seed $2M–$50M; Series A $3.1M–$100M; Series B $11M–$200M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- Xinghuo Chenguang — Xinghuo Chenguang is a hard-tech company focusing on semiconductor chips and optoelectronic interconnect technologies.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 192
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$85M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors. Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 714
- Round size: Seed $1.4M–$74M; Series A $2.9M–$52M; Series B $10M–$137M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Camera360 — Camera360 is a mobile phone camera application. Through a variety of solutions, including Camera360 Ultimate, HelloCamera, Movie360, Pink360, Camera360 Cloud, Camera360 SDK and Web Camera360, Camera360 hopes to build an ecosystem for the modern creatives to capture, compose and share the beautiful moments of their lives.
- DiffuSpace — DiffuSpace is an artificial intelligence initiative dedicated to building diffusion language models to establish a new foundation model paradigm beyond traditional autoregression. Instead of generating text sequentially token by token, their technology focuses on thinking globally and evolving through uncertainty.
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 254
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
- Connexus Therapeutics — Connexus Therapeutics is a private, venture-backed biotechnology company specializing in the discovery and development of next-generation small-molecule drugs for oncology treatment .
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 161
- Round size: Seed $1.4M–$20M; Series A $1.5M–$35M; Series B $10M–$57M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Guangyu Xinchen — Guangyu Xinchen is a semiconductor company that provides research and development of large-scale model chips for edge devices.
- Guoke Optoelectronics — Guoke Optoelectronics is a national high-tech enterprise integrating comprehensive capabilities in materials processing, chip design, integrated packaging, optoelectronic devices, application algorithms, and system integration. With the mission of "lighting the way for our peers," Guoke Optoelectronics is committed to becoming a globallyleading company in silicon photonics chip technology and overall solutions
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China. Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in China or on markets related to China. Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services. Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc. As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 523
- Round size: Series A $2.9M–$93M; Series B $12M–$100M; Series C $15M–$200M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- DiffuSpace — DiffuSpace is an artificial intelligence initiative dedicated to building diffusion language models to establish a new foundation model paradigm beyond traditional autoregression. Instead of generating text sequentially token by token, their technology focuses on thinking globally and evolving through uncertainty.
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Internet, Software, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1237
- Round size: Seed $600k–$44M; Series A $2M–$100M; Series B $6.2M–$110M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Manus AI — Manus is the action engine that goes beyond answers to execute tasks, automate workflows, and extend your human reach.
- SemiGraph — SemiGraph focuses on the research, development, and implementation of "3D intelligent interaction + ultimate aesthetics."
- Tian Keyu’s Research Lab — Tian Keyu’s Research Lab is a research lab of Tian Keyu.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stage startups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Medical
- Stage:Series A, Angel, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 244
- Round size: Seed $1.4M–$14M; Angel $447k–$10M; Series A $1.6M–$28M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $144M in 2015
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Flysound — Flysound is a hearing technology company focused on making advanced AI-powered hearing aids affordable and accessible. Its products combine AI sound processing, Bluetooth connectivity, app-based personalization, and rechargeable convenience. With a focus on innovation, quality, and user-friendly design, Flysound aims to help people hear moreclearly and stay connected to everyday life.
- Clarify intelligence — Clarify Intelligence is an artificial intelligence technology company focused on the research, development, and deployment of AI-driven software and intelligent solutions. The company specializes in developing foundational AI platforms, application software, and advanced AI algorithms to support a wide range of industry use cases.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, United States, South Korea
Investor stats
- Total investments: 400
- Round size: Series A $2.9M–$40M; Series B $8.8M–$56M; Venture - Series Unknown $1.5M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfolio sources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 105
- Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $21M–$128M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
- Allygen Biologics — Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 44
- Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB, and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 651
- Round size: Seed $1.4M–$29M; Series A $1.6M–$100M; Series B $7.5M–$141M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for many years focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 334
- Round size: Series A $2.9M–$100M; Series B $14M–$149M; Series C $30M–$220M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Synapath — Synapath focuses on using embodied intelligence and robotics technology to create clever systems for making decisions for multi-domain applications that are intelligent.
- Blue Pivot Energy Technology — Blue Pivot Energy Technology is a nuclear energy technology company focused on the independent development and commercialization of integrated water-cooled small modular reactors (SMRs).
- Deep Space Matrix Technology — Deep Space Matrix Technology's long-term objective is to benchmark against SpaceX and progressively construct a Chinese equivalent of an integrated air, space, and sea superintelligent system.
They are an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect in China and to partner with entrepreneurs with dedication and the highest standard.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 180
- Round size: Seed $10M–$84M; Series A $3.1M–$73M; Series B $7.6M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Dongsheng Aerospace — Dongsheng Aerospace specializes in the creation and production of entire spacecraft as well as essential onboard parts, such as computing and internet satellites.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special funds and have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises. GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Manufacturing
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 245
- Round size: Angel $425k–$3.1M; Series A $1.5M–$60M; Series B $3M–$150M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
- Chiplight Technology — Chipligh Technology develops optical interconnect and silicon photonics solutions for AI computing clusters.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 281
- Round size: Seed $2.5M–$30M; Series A $1.5M–$42M; Series B $3M–$103M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- MindMotion — MindMotion is an electronics company that supplies general-purpose 32-bit MCU products and solutions. The company's MM32 MCU products developed by the company based on the Arm Cortex-M series cores have four series of F/L/SPIN/W, more than 200 models, and a cumulative delivery of more than 300 million units, ranking in theforefront of local general-purpose 32-bit MCU companies.MindMotion was founded in 2011 and is headquartered in Shanghai, China.
- Yitang Technology — Yitang Technology is a developer specializing in high-speed and high-precision placement machines. The company is dedicated to the research and development (R&D) of these advanced machines, as well as the industrialization of intelligent production line solutions.
- Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Investors of Gaorong Capital include world-class sovereign wealth funds, university endowment funds, family foundations, pension funds and fund of funds, as well as successful entrepreneurs, including founders and managements of Tencent, Alibaba, Baidu, JD, Xiaomi, Focus Media and VIPShop. They will provide with valuable industry resources, entrepreneurial experience, and global perspectives.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 371
- Round size: Seed $2.8M–$100M; Series A $1.6M–$75M; Series B $14M–$110M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Anew Labs — Anew Labs develops generative AI platforms and foundation models to accelerate drug discovery, including protein structure prediction, antibody design, and cellular dynamics forecasting. The company integrates its computational engines with experimental feedback to advance pipelines targeting diseases like inflammatory conditions. Its business model centers on side-by-side collaboration between machine learning researchers and biotechnology experts to create synthesizable molecular pathways and clinical candidates.
- Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
- Sequence Technology — Sequence Technology emphasizes in the production of polymer materials used in the semiconductor manufacturing process.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 more successfully exit. The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Semiconductor
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 367
- Round size: Seed $1.4M–$20M; Series A $2.8M–$51M; Series B $7.2M–$50M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Lanxin Computing — Lanxin Computing is a high-performance chip design company that focuses on the research and development of CPUs with RISC-V ecosystems.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 63
- Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
- Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
- Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Manufacturing
- Stage:Seed, Angel, Series A
- Geography: China, Singapore, United States
Investor stats
- Total investments: 96
- Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$29M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- D-Robotics — Accelerate development with D-Robotics RDK developer kits & open-source tools for edge AI & embodied robotics. Boost performance up to 128 TOPS. Shop now!
- Xieyue Intelligent — Xieyue Intelligent focuses on the research and development of embodied intelligence technology.
- DeepPu Intelligence — DeepPu Intelligence is a high-tech enterprise specializing in the research, development, and innovation of intelligent robotic technologies. The company focuses on creating advanced robotic systems that integrate artificial intelligence, machine vision, and automation to serve a wide range of industries, including manufacturing, logistics,healthcare, and service sectors.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies. Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 456
- Round size: Series A $2.9M–$153M; Series B $12M–$219M; Series C $16M–$300M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $1.4B in 2023
Portfolio highlights
- KMC Solutions — Build global teams in the Philippines and Colombia with KMC's Employer of Record, recruitment, HR, payroll, and flexible office solutions.
- LifeLabs Design — LifeLabs patented warming & cooling technology allows for comfort across extreme temperatures. Explore our dedication to producing sustainable & eco-friendly fabrics.
- DayOne — GDS International portfolio currently comprises approximately 480 MW of data center capacity in service and under construction and an additional 590 MW held for future development across strategic locations in Hong Kong, Singapore, Malaysia (Johor), Indonesia (Batam), and Japan (Tokyo).
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 364
- Round size: Series A $1.6M–$30M; Series B $12M–$145M; Venture - Series Unknown $1.4M–$101M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- CVSENS — CVSENS is a developer and supplier of CMOS image sensor chips for the CIS industry.
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors. As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors. Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 84
- Round size: Seed $1.4k–$28M; Series A $297k–$37M; Series B $7.3M–$58M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Bioyond Tech — Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc. Examples of their investment portfolio: YueBoo、Hunan zhongli、 Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, France
Investor stats
- Total investments: 105
- Round size: Seed $1.5M–$50M; Series A $1.6M–$20M; Series B $9.9M–$30M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
- Zhongke Hecheng — Zhongke Hecheng is the industrialization company of the Energy Research Institute of the Hefei Comprehensive National Science Center. The company focuses on the overall design, production, and sales of green ammonia synthesis equipment , and is committed to providing modular, flexible ammonia synthesis equipment and sustainable ammonia production solutions.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. We believe that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Seed, Series A, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 762
- Round size: Seed $121k–$14M; Angel $425k–$3M; Series A $873k–$22M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Manus AI — Manus is the action engine that goes beyond answers to execute tasks, automate workflows, and extend your human reach.
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential. They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many years of remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 83
- Round size: Seed $2.5M–$30M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance. Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem. Legend Star is the independent early-stage investment arm of Legend Holdings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Robotics
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 174
- Round size: Seed $1.5M–$19M; Angel $425k–$7.8M; Series A $1.5M–$52M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — raised $127M in 2018
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Ubot Robotics — Ubot Robotics is dedicated to developing leg-and-foot bionic robots and has built a diverse range of bipedal, quadrupedal, hexapodal, and other leg-and-foot bionic robots.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 28
- Round size: Seed $13M–$14M; Series A $14M–$30M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- ClonOrgan — ClonOrgan has developed a technology to humanize pig cells that will grow into human-compatible organs.The business specializes in xenotransplantation and has a one-stop R&D platform that includes raising gene-edited pigs, preclinical testing, and breeding. It is dedicated to addressing the critical shortage of clinical organ transplantationand creating the organ factory of the future.ClonOrgas was established in 2005 in Chengdu, Sichuan.
- Glimmer Gene — Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights.
- Lingsheng Technology — Lingsheng Technology is a developer of embodied intelligent robots.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatment and healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Manufacturing, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 335
- Round size: Seed $1.5M–$100M; Series A $1.5M–$30M; Series B $3.1M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Memory tensor — Memory tensor designed with a focus on systematic innovation, grounded firmly in fundamental principles, serves as a powerful tool for scalable and adaptable intelligence. Its architecture emphasizes three core attributes: low cost, ensuring economic feasibility and accessibility; low illusion, reducing overfitting and minimizing hallucinations ormisleading outputs; and high generalization.
- Langsilicon Technology — Langsilicon Technology is an electronic component R&D firm that specializes in the design, development, and sales of silicon-based passive components (capacitors, inductors, and resistors).
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 51
- Round size: Seed $2.8M–$20M; Angel $434k–$100M; Series A $14M–$37M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Allygen Biologics — Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics.
- Danuo Intelligent Technology — Danuo Intelligent Technology is dedicated to promoting the application of trustworthy AI in the life sciences field.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 347
- Round size: Seed $1.4M–$65M; Series A $1.5M–$74M; Series B $8M–$150M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- SemiGraph — SemiGraph focuses on the research, development, and implementation of "3D intelligent interaction + ultimate aesthetics."
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Software
- Stage:Angel, Series A, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 321
- Round size: Seed $1M–$14M; Angel $417k–$3.1M; Series A $1.4M–$25M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2025
Portfolio highlights
- Quantex — Quantex is committed to focusing on the next generation of information technology and integrated circuit fields, and is dedicated to the in-depth research and development of 3.2T/6.4T photonic integrated chips (PIC), optical modules and CPO (co-packaged optics) solutions, leading the localization of high-end optical transmission chips.
- XinYang Micro — Xinyangwei is an early stage underwater sensing chip startup specializing in CMUT (Capacitive Micromachined Ultrasonic Transducer) technology. The company provides integrated acoustic sensing modules and 3D imaging components designed to give pool cleaning robots intelligent near field path planning and mapping capabilities.
- Sequence Technology — Sequence Technology emphasizes in the production of polymer materials used in the semiconductor manufacturing process.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internet sectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, India
Investor stats
- Total investments: 618
- Round size: Seed $1M–$74M; Series A $1.5M–$41M; Series B $8.2M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- DiffuSpace — DiffuSpace is an artificial intelligence initiative dedicated to building diffusion language models to establish a new foundation model paradigm beyond traditional autoregression. Instead of generating text sequentially token by token, their technology focuses on thinking globally and evolving through uncertainty.
- Clarify intelligence — Clarify Intelligence is an artificial intelligence technology company focused on the research, development, and deployment of AI-driven software and intelligent solutions. The company specializes in developing foundational AI platforms, application software, and advanced AI algorithms to support a wide range of industry use cases.
ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Electronics
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 168
- Round size: Series A $8.6M–$100M; Series B $3M–$129M; Series C $14M–$75M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Parylene — Parylene is a provider of protective coating application solutions
- Alnan Aluminium — Alnan Aluminium is an industrial company that offers aluminum products, fabrication, and non-ferrous metal smelting services.
- Huaguan Biotechnology — Huaguan Biotechnology provides high-quality integrated drug research and development services for customers. This includes Sihuan Pharmaceutical, Sichuan Kelun, Tianjin Tasly, Beijing Yabao, Huasu Pharmaceutical, and other well-known domestic pharmaceutical companies, as well as Suzhou Amate, Shanghai Fuqi, Jiangsu Ya Sheng, and other scientificand technological innovation enterprises, the team development ability has been recognized by the industry and has attracted a number of listed companies such as Sihuan Pharmaceutical to inject capital.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 106
- Round size: Angel $52k–$1.9M; Series A $1.5M–$25M; Series B $3M–$257M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- Zhaomo Vacuum — Zhaomo Vacuum is an enterprise integrating R&D, production, commissioning, and service of vacuum chambers.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Robotics
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 243
- Round size: Seed $1.9M–$28M; Series A $1.5M–$43M; Series B $8M–$123M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- Sondit — Sondit specializes in R&D and manufacturing of civilian radar systems. It includes intelligent transportation, intelligent security, vehicle-road coordination, and other fields. It engaged in traffic information monitoring and urban traffic management in the field of the intelligent transportation industry.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 154
- Round size: Angel $444k–$15M; Series A $1.5M–$73M; Series B $8.5M–$90M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- Allygen Biologics — Allygen Biologics is a biotechnology company that provides research and development of targeted conjugate therapeutics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from early research to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, Singapore, Norway
Investor stats
- Total investments: 77
- Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Yatsen Holding — Yasten provides high-quality fashion makeup products.
- kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Canada
Investor stats
- Total investments: 227
- Round size: Seed $4.5M–$44M; Series A $1.5M–$46M; Series B $10M–$100M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- MOSS Intelligence — MOSS Intelligence is a high-tech enterprise in China focusing on the research and commercialization of next-generation strong interactive basic models, aiming to advance the development of highly adaptive, multimodal AI systems that enable natural, context-aware human–machine interaction while supporting scalable applications across industries suchas education, enterprise services, robotics, and digital ecosystems.
- Leadsynbio — Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzymeengineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
5Y Capital is a firm engaged in providing early-stage venture investments. It was formerly known as Morningside Venture Capital. The investment firm manages USD 5bn in dual-currency funds in USD and RMB, backed by world-renowned sovereign wealth funds, family offices, fund of funds, university endowments, pensions, and foundations. It is an investment firm of Morningside Group. It was headquartered in Xuhui, Shanghai, China in 2008 by Ken Shi and Richard Liu.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 351
- Round size: Series A $3M–$100M; Series B $10M–$150M; Series C $32M–$400M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- DaSouChe — DaSouChe is the AI application infrastructure for China’s used car industry. According to CIC, the Company has held an over 90% market share in operating systems for China’s used car dealers since at least 2021. Building on this digital foundation, DaSouChe further supports used car dealers with essential transaction services across theirworkflows. Beyond used car dealers, the Company also works with other auto merchants, including OEMs, authorized dealers and new car brokers. Its services further engage and benefit thousands of dealers’ collaborators, such as inspectors, transporters and other internet platforms, creating an ecosystem with used car dealers at its center. The Company’s unwavering focus on used car dealers’ success underpins everything it does and has made its mission critical to their business.
- BASAL Intelligence — BASAL Intelligence is an artificial intelligence research and development company that focuses on embodied AI and robotic self-evolution technology. The company develops action-native in-context embodied foundation models that allow robots to perform in-context learning and adapt to new tasks and environments on the fly. Its core research includes creating cross-embodied foundational models, latent world models, and unified action space frameworks to bridge the gap between simulation and real-world deployment. Ultimately, the company aims to enable robots to autonomously generalize and evolve their skills across diverse physical hardware and complex scenarios.
- Tian Keyu’s Research Lab — Tian Keyu’s Research Lab is a research lab of Tian Keyu.
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 68
- Round size: Seed $8M–$50M; Series A $14M–$43M; Series B $10M–$159M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- BioGeometry — BioGeo is an innovative digital startup that specializes in using generative AI in protein creation. BioGeo is dedicated to producing programmable proteins from scratch and utilizing them in synthetic biology and biomedicine by employing artificial intelligence-driven techniques to create links between protein sequence, structure, and function.
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
- Beyond Therapeutics — Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.
Shunxi Fund is an investment Fund. It is managed by Beijing State-owned Capital Operations and Management.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: China
Investor stats
- Total investments: 77
- Round size: Seed $2.4M–$20M; Series A $3M–$78M; Series B $14M–$90M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- Dingxi Zhichuang — Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment.
- Isin Intelligent — Isin Intelligent is a cloud computing service provider that utilizes FPGAs (a type of semi-custom chip) to realize a new computing paradigm in microwave photonics and optoelectronic parametric oscillators, providing novel solutions to combinatorial optimization problems widely existing in many fields in my country (transportation, finance,pharmaceutical R&D, artificial intelligence, etc.).
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 767
- Round size: Series A $9M–$116M; Series B $23M–$148M; Series C $19M–$160M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Bonovo Orthopedics —
Lapam Capital is a healthcare-focused venture capital firm.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 45
- Round size: Series A $13M–$40M; Series B $15M–$82M; Series C $4.5M–$100M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
- Lingtai Biotechnology — Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.
Innoangel Fund is an investment firm that invests in early stage companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Manufacturing, Robotics
- Stage:Angel, Seed, Series A
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 305
- Round size: Seed $452k–$29M; Angel $425k–$14M; Series A $1.5M–$28M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Dongthink — Dongthink transform real-world actions and interactions into reusable, scalable training data.
- Weilan Deep-Sea — Weilan Deep-Sea focuses on the global underwater ocean observation field, with its core product being distributed underwater observation systems that integrate advanced sensing, data transmission, and intelligent monitoring technologies to enable long-term, wide-area, and high-precision observation of oceanographic, environmental, and geologicalprocesses.
- Qianjue Technology — Qianjue Technology is a company that created the first full-stack application-level robot model and offers cloud-based artificial intelligence solutions to robot manufacturers.
LYFE Capital is a pure play healthcare focused investment firm. We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters inSingapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe. LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, France
Investor stats
- Total investments: 80
- Round size: Series A $11M–$85M; Series B $15M–$148M; Series C $14M–$142M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
- Starna Therapeutics — Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.
- ALLYRNA Pharmaceuticals — ALLYRNA, an innovative small molecule drug developer focused on first-in-class drug development, has established a unique platform for radiotherapy and immunotherapy sensitizers.
Biotechnology Investor funding in China at a glance
Stats across 3.1k deals from 3.4k investors.
Access all 3405 investors in China Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 3405 investors investing in China Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!